[The treatment of multiple sclerosis with beta-interferon 1a]
| Autor: | V M, Rivera |
|---|---|
| Rok vydání: | 2000 |
| Předmět: | |
| Zdroj: | Revista de neurologia. 31(5) |
| ISSN: | 0210-0010 |
| Popis: | Preliminary studies (phase III) have shown that treatment with beta-interferon 1a (avonex) is effective in diverse aspects of relapsing/remitting multiple sclerosis (RRMS). The present study discusses results of an opened prolonged (phase IV) trial at the Baylor/Methodist International Multiple Sclerosis Center using 6 MIU by intramuscular injection once a week.Clinical measurements: EDSS and Patient's Subjective Self-Evaluation (PSSE) and magnetic resonance (MR) were utilized every three months in 300 patients studied between 1996-1999. Patients with RRMS (71.8%) and secondarily progressive multiple sclerosis (SPMS) (28.2%) were included.Global clinical improvement parameter integration was 22.7% and clinical stabilization 39.4%. MR did not show quantitative alterations for either group. Sixteen patients abandoned treatment and 16 (5.3%) had relapses correlated by MR activity; 34.9% remained stable by EDSS and magnetic resonance findings but deteriorated subjectively by PSSE (62% has SPMS).This phase IV study indicates that prolonged treatment of RRMS and SPMS with avonex maintains a positive effect in 62.1% of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|